Share
Services
The internationally renowned Fresenius Helios heart center in Leipzig is celebrating its thirtieth anniversary. Representatives from the political sphere, research community, and hospital have commended the heart center and its history of cutting-edge medicine at the Helios hospital in Leipzig. Further guests beside the Saxon Minister-President included Leipzig’s Lord Mayor Burkhard Jung and the Rector of Leipzig University, Professor Eva Inés Obergfell.
Robert Möller, Fresenius Management Board member and Helios CEO:
“The Fresenius promise of ‘Committed to Life’ also brings a responsibility with it. We not only save lives, but also improve both the quality of people’s lives and their health. We provide access to affordable, innovative medicine of the highest quality. All of this is impressively demonstrated here at the heart center. I am delighted that we are today considered a cornerstone of the medical infrastructure here in Leipzig and the wider region, and cooperate with Leipzig University in the areas of pediatric cardiology, cardiac surgery, and cardiology. This in turn enables us to drive future-oriented projects in both clinical and research fields. It is a success story of a trusting cooperation on an equal footing with Leipzig University and the Free State of Saxony. In its 30-year history, the Leipzig Heart Center has been involved in state-of-the-art diagnostic and therapeutic procedures and a variety of research initiatives that extend far beyond national borders and earned itself a global reputation.”
Michael Kretschmer, Minister-President of the Free State of Saxony:
“Leipzig Heart Center has stood for cutting-edge medicine and medical innovation for 30 years now. Patients of all ages know that they will receive first-class care for their heart problems here. Other hospitals in the region can also rely on the specialist knowledge of the experts in Leipzig. This makes the heart center an important cornerstone of medical care in our region. The Free State of Saxony will continue to support the heart center in the future. It is investing in the renovation and expansion of pediatric cardiology as well as in digitalization so that people can continue to receive the highest level of care.”
Cutting-edge medicine making history
The Leipzig Heart Center has achieved countless milestones over the past 30 years: Doctors and nurses have used state-of-the-art technology to so far perform over 100,000 heart operations, more than 270,000 cardiac catheterizations, and 100,000 ablations, helping to improve the lives of around 500,000 patients. Particularly worthy of mention here are the advances in minimally-invasive heart surgery, interventional cardiology, and electrophysiology, which have made the Leipzig Heart Center a pioneer in its field.
The manifold scientific and clinical achievements mean that Leipzig Heart Center is a leader in many specialist areas – it has the world’s largest heart valve clinic, for example. The cardiology and cardiac surgery departments are among the largest specialist university departments in Germany. The department of pediatric cardiology is the only heart center specifically for children in Saxony, Saxony-Anhalt, and Thuringia. Today, more than 1,450 employees from 50 nations and countless specialized medical fields devote themselves to heart health here.
Helios an authority on cardiac medicine in Germany
As a core component of the Fresenius Care Provision Platform, Helios stands for excellence and high-quality medical outcomes along the entire patient journey. Fresenius Helios operates six heart centers in Germany, namely in Karlsruhe, Krefeld, Leipzig, Siegburg, Schwerin, and Wuppertal. The centers’ staff work together closely within highly specialized, in part cross-regional teams. Making them the practical expression of Fresenius Helios’ medical cluster and specialization strategy.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2025 in Germany, has been set at 4.41%. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.
The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2025 in Germany, has been set at 4.41%. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.
Morgan Stanley Annual Global Healthcare Conference Presentation
Fresenius continues streamlining the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi transferred the ownership of its subsidiary Laboratorio Sanderson S.A., Chile, to Medifarma, a multinational pharmaceutical company from Peru with a strong presence in Latin America. This divestment includes the IV Laboratorio Sanderson plant in Santiago de Chile. Medifarma will continue the manufacturing of the existing portfolio of products in Chile. Fresenius Kabi remains committed to the Chilean as well as South American markets and will continue its presence accordingly. This is another step to reduce complexity and optimize utilization in Fresenius Kabi’s global manufacturing network.
Fresenius continues streamlining the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi transferred the ownership of its subsidiary Laboratorio Sanderson S.A., Chile, to Medifarma, a multinational pharmaceutical company from Peru with a strong presence in Latin America. This divestment includes the IV Laboratorio Sanderson plant in Santiago de Chile. Medifarma will continue the manufacturing of the existing portfolio of products in Chile. Fresenius Kabi remains committed to the Chilean as well as South American markets and will continue its presence accordingly. This is another step to reduce complexity and optimize utilization in Fresenius Kabi’s global manufacturing network.
